Education
About Us
Working with TipRanks
Follow Us
Defence Therapeutics (DTCFF)
OTHER OTC:DTCFF
DTCFF Stock Chart & Stats
$0.54
$0.06(15.36%)
At close: 4:00 PM EST
$0.54
$0.06(15.36%)
Day’s Range― - ―
52-Week Range$0.27 - $1.16
Previous CloseN/A
Volume8.00K
Average Volume (3M)599.00
Market Cap
$26.81M
Enterprise Value$50.99M
Total Cash (Recent Filing)$2.32M
Total Debt (Recent Filing)$2.97M
Price to Earnings (P/E)―
Beta-0.50
Next Earnings
Mar 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding54,725,370
10 Day Avg. Volume40
30 Day Avg. Volume599
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-959.13
Enterprise Value/Ebitda-15.68
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Defence Therapeutics News
DTCFF FAQ
What was Defence Therapeutics’s price range in the past 12 months?
Defence Therapeutics lowest stock price was $0.27 and its highest was $1.16 in the past 12 months.
What is Defence Therapeutics’s market cap?
Defence Therapeutics’s market cap is $26.81M.
When is Defence Therapeutics’s upcoming earnings report date?
Defence Therapeutics’s upcoming earnings report date is Mar 03, 2026 which is in 69 days.
How were Defence Therapeutics’s earnings last quarter?
Currently, no data Available
Is Defence Therapeutics overvalued?
According to Wall Street analysts Defence Therapeutics’s price is currently Overvalued.
Does Defence Therapeutics pay dividends?
Defence Therapeutics does not currently pay dividends.
What is Defence Therapeutics’s EPS estimate?
Defence Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Defence Therapeutics have?
Defence Therapeutics has 54,725,370 shares outstanding.
What happened to Defence Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Defence Therapeutics?
Currently, no hedge funds are holding shares in DTCFF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Defence Therapeutics
Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Technical Analysis
Oncolytics Biotech
―
Oncolytics Biotech
―
Helix BioPharma
―
Microbix Biosystms
―
Medmira
―
NurExone Biologic
―